|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào)：L175804 |
| 產(chǎn)品名稱：Lapatinib-13C2,15N |
| 產(chǎn)品CAS：1246819-07-7 |
| 規(guī)格含量：5mg |
| 產(chǎn)品價(jià)格：面議 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
L175804 |
| 名稱: |
Lapatinib-13C2,15N |
| 別名: |
N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine-13C2,15N; GSK 572016-13C2,15N; GW 572016-13C2,15N; GW 572016X-13C2,15N; |
| CAS號(hào): |
1246819-07-7 |
| 參考CAS號(hào): |
231277-92-2-unlabelled |
| 分子式: |
C??¹³C?H??ClFN?¹?NO?S |
| 外觀: |
Pale Yellow to Yellow Solid |
| 熔點(diǎn): |
>195°C (dec.) |
| 分子量: |
584.04 |
| 儲(chǔ)存: |
-20?C Freezer |
| 溶解度: |
DMSO (Slightly), Methanol (Very Slightly) |
| 種類: |
Standards; Isotopic Labeled Analogues; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| 應(yīng)用: |
Labelled Lapatinib (L175800). Reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Antineoplastic. |
| 參考文獻(xiàn) |
|
|
|
|
?您的位置：
